CIBC Private Wealth Group LLC Grows Position in Boston Scientific Corporation $BSX

CIBC Private Wealth Group LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,387,686 shares of the medical equipment provider’s stock after purchasing an additional 9,670 shares during the period. CIBC Private Wealth Group LLC’s holdings in Boston Scientific were worth $135,480,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in BSX. Steph & Co. purchased a new position in shares of Boston Scientific during the third quarter valued at approximately $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp lifted its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Finally, United Community Bank boosted its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on BSX shares. Truist Financial cut their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. TD Cowen lowered their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. JPMorgan Chase & Co. cut their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Finally, Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $107.32.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains, with UBS keeping a “buy” rating despite trimming its price target — this preserves broker confidence and highlights upside vs. current levels. Benzinga
• Positive Sentiment: Market writeups note the pullback may be overdone given solid recent financials (quarterly revenue and EPS strength and guidance), which supports a rebound narrative among value- and momentum-seeking investors. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Positive Sentiment: News summaries explaining why BSX outpaced the market today help attract short-term flows and algos reacting to momentum and analyst notes. Why Boston Scientific (BSX) Outpaced the Stock Market Today
• Neutral Sentiment: Some investor notices and law-firm solicitations are informational and can amplify trading volume even if they don’t change fundamentals immediately; these items tend to keep the stock volatile near-term. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Multiple securities class-action filings and numerous law‑firm lead‑plaintiff solicitations allege disclosure problems around the U.S. Electrophysiology unit; this raises potential litigation risk, settlement exposure and near-term headline risk that can weigh on valuation. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Numerous law firms (Rosen, Pomerantz, Faruqi, Bernstein Liebhard, Robbins Geller, etc.) have issued alerts about the May 4 lead-plaintiff deadline — repetitive alerts keep legal risk top of mind for investors and can suppress sentiment until the cases are resolved or dismissed. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $71.19 on Wednesday. The firm has a market cap of $105.64 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 0.98 and a beta of 0.69. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average is $81.42 and its 200 day moving average is $92.71.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.